On Jonusry $1,2023,$ Puloski, Incorporated, acquired a $60$ percent interest in the common stock of Sheridan, Incorporated, for $$348,000.$ Sheridon's book value on that date consisted of common stock of $$100,000$ and retoined earnings of $$205,800.$ Also, the acquisition$-$dste fair volue of the $40$ percent noncontrolling interest was $$232,000.$ The subsidiory held patents $($with o $10-$year remaining life$)$ that were undervalued within the compony's accounting records by $$52,300$ and also had unpatented technology $(15$yeor estimated remaining life$)$ undervalued by $$46,800.$ Any remaining excess acquisition$-$date foir volue was assigned to an indefinitelived trode name. Since ocquisition, Pulaski hos applied the equity method to its Investment in Sheridon account. At year$-$end, there are no intro$-$entity poyobles or receivobles.

Intra$-$entity inventory sales between the two componies hove been made as follows:

$\backslash$table$[[,$Transfer Price,Ending Balance $($at$,],[$Year cost to Pulagia,to sheridan,transfer price$),],[2023,$$$121,500,$$$151,875,$$$0,625$